Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing’s syndrome.The setback cast doubt on CORT’s pipeline strength and triggered a sharp re-evaluation by analysts. It underscores the market’s sensitivity to regulatory developments…
Logan Mohtashami, a senior HousingWire analyst, believes mortgage rate stability – not rate cuts – will be the key…
On December 1st, famed investor Jim Cramer looked into the camera on CNBC’s Mad Money and made a provocative…
Mark Mahaney – a senior Evercore ISI analyst – has named his top internet stock picks for 2026, highlighting…
The market value of Nio shares increased during the first week of the month because investors analyzed positive fourth-quarter…
China’s economy closed the year with a modest improvement in momentum, as official data showed factory activity expanding in…
Asian markets closed out the year on a subdued note amid thin holiday trading, capping a year of strong…
China is set to tighten controls on silver exports from Thursday, extending its oversight over a metal that has…
The IBEX 35 Index had a great performance in 2025 and was one of the best-performing global benchmarks. It…